Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Ofatumumab Dose-finding in RRMS Patients
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Mitoxantrone for multiple sclerosis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
HL-A antigens and multiple sclerosis.
Optimizing IFN Beta - 1B Dose (Optims)
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.

Pages